Karo Pharma AB
Karo Pharma: ANNUAL GENERAL MEETING 2019 IN KARO PHARMA AKTIEBOLAG
STOCKHOLM, 16 May 2019
At todays annual general meeting of Karo Pharma, the following
decisions were passed.
The annual general meeting resolved to adopt the income statement and
balance sheet for the group and the parent company. The annual
general meeting resolved that available funds, including the earnings
for the year, were to be carried forward.
The annual general meeting resolved that the board of directors shall
consist of seven board members without deputy directors by
re-election of Bo Jesper Hansen, Erika Henriksson, Vesa Koskinen, Åsa
Riisberg and Håkan Åström as well as election of Eva Sjökvist Saers
and Flemming Ørnskov as new board members. Flemming Ørnskov was
elected as from 31 October 2019. The annual general meeting
re-elected Bo Jesper Hansen as chairman of the board.
Remuneration to the board of directors was determined to SEK
2,250,000, of which the chairman is entitled SEK 600,000, and each of
the other board members are entitled SEK 300,000, however, the
remuneration to Flemming Ørnskov shall be reduced pro rata in
relation to his term and hence amount to SEK 150,000. The elected
board members that are active at EQT - Erika Henriksson, Vesa
Koskinen and Åsa Riisberg - have announced that they remit their
respective remuneration to the help and charity organisation
The accounting firm Ernst & Young AB was elected as new auditor for
the period until the end of the annual general meeting 2020.
The annual general meeting further resolved, in accordance with the
board of directors proposal, to adopt guidelines for remuneration
for senior management.
The annual general meeting resolved, in accordance with the board of
directors proposal, to authorise the board of directors, for the
period until the next annual general meeting, on one or more
occasions, to decide on the transfer of own shares. The reason for
the authorisation is to expand the companys financial flexibility,
to enable acquisitions through payment with shares, to provide the
company with new capital and/or new shareholders of strategic
importance to the company, and/or acquisitions of other companies or
operations. Transfer of shares may be carried out of a maximum of all
own shares held by the company at the time of the board of directors
resolution on transfer.
The annual general meeting also resolved, in accordance with the board
of directors proposal, to authorise the board of directors to - on
one or more occasions and until the end of the next annual general
meeting - decide on the issue of shares. The number of shares to be
issued on the basis of the authorization shall not exceed 10 per cent
of the registered share capital at the time of the issue decision.
The issue may be made with or without deviation from the
shareholders preferential rights, as well as on terms regarding
payment in kind, by right of set-off or against other terms.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
Mats-Olof Wallin, CFO, +4676 002 60 10, email@example.com
ABOUT KARO PHARMA
Karo Pharma is a Specialty Pharma company, which develops and markets
products for pharmacies as well as directly to the healthcare sector.
Karo Pharma is listed on Nasdaq Stockholm Mid Cap.
The information was submitted for publication, through the agency of
the contact person set out above, on 16 May, at 17.30 CEST. This
press release is also available at www.karopharma.se and